雷贝拉唑三联疗法治疗HP阳性消化性溃疡的疗效研究
|
摘要
目的 :探讨雷贝拉唑三联疗法治疗幽门螺杆菌(HP)阳性消化性溃疡的疗效及安全性。方法 :选取我院收治的HP阳性消化性溃疡患者108例,依照随机数字表法分为观察组和对照组,各54例。对照组采取奥美拉唑三联疗法[奥美拉唑(20 mg,bid)+阿莫西林(1 g,bid)+克拉霉素(500 mg,bid)]治疗,观察组采取雷贝拉唑三联疗法[雷贝拉唑(20 mg,bid)+阿莫西林(1 g,bid)+克拉霉素(500 mg,bid)]治疗。比较两组治疗效果、HP根除率、不良反应发生率与治疗后6个月溃疡复发率。结果 :观察组治疗效果优于对照组,差异有统计学意义(P <0.05);治疗后观察组HP根除率为90.74%,高于对照组的75.93%,差异有统计学意义(P <0.05);两组不良反应总发生率比较,差异无统计学意义(P> 0.05);观察组溃疡复发率低于对照组,差异有统计学意义(P <0.05)。结论 :雷贝拉唑三联疗法治疗HP阳性消化性溃疡可显著提高治疗效果,提升HP根除率,降低溃疡复发风险,且安全性高。
Objective: To investigate the efficacy and safety of rabeprazole triple therapy in the treatment of Helicobacter pylori(HP)-positive peptic ulcer. Methods: 108 patients with HP-positive peptic ulcer admitted to our hospital were enrolled and randomly divided into an observation group and a control group, 54 cases in each group. The patients in the control group were given omeprazole triple therapy [omeprazole(20 mg, bid) + amoxicillin(1 g, bid) + clarithromycin(500 mg, bid)], and the patients in the observation group were given rabeprazole triple therapy [rabeprazole(20 mg, bid) + amoxicillin(1 g, bid) + clarithromycin(500 mg, bid)]. The therapeutic effect, HP eradication rate, incidence of adverse reactions and ulcer recurrence rate after 6 months of treatment were compared between the two groups. Results: The therapeutic effect in the observation group was better than that in the control group, with statistically significant difference(P<0.05). The HP eradication rate in the observation group was 90.74%, which was higher than 75.93% in the control group, with statistically significant difference(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). The recurrence rate of ulcers in the observation group was lower than that in the control group, with statistically significant difference(P<0.05). Conclusion: The rabeprazole triple therapy for HP-positive peptic ulcer can significantly improve the therapeutic effect, improve HP eradication rate and reduce the risk of ulcer recurrence, and has high safety.
Objective: To investigate the efficacy and safety of rabeprazole triple therapy in the treatment of Helicobacter pylori(HP)-positive peptic ulcer. Methods: 108 patients with HP-positive peptic ulcer admitted to our hospital were enrolled and randomly divided into an observation group and a control group, 54 cases in each group. The patients in the control group were given omeprazole triple therapy [omeprazole(20 mg, bid) + amoxicillin(1 g, bid) + clarithromycin(500 mg, bid)], and the patients in the observation group were given rabeprazole triple therapy [rabeprazole(20 mg, bid) + amoxicillin(1 g, bid) + clarithromycin(500 mg, bid)]. The therapeutic effect, HP eradication rate, incidence of adverse reactions and ulcer recurrence rate after 6 months of treatment were compared between the two groups. Results: The therapeutic effect in the observation group was better than that in the control group, with statistically significant difference(P<0.05). The HP eradication rate in the observation group was 90.74%, which was higher than 75.93% in the control group, with statistically significant difference(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). The recurrence rate of ulcers in the observation group was lower than that in the control group, with statistically significant difference(P<0.05). Conclusion: The rabeprazole triple therapy for HP-positive peptic ulcer can significantly improve the therapeutic effect, improve HP eradication rate and reduce the risk of ulcer recurrence, and has high safety.
引文
[1]何小谷,方向明,汪勇,等.Hp阳性消化性溃疡患者血清TGF-β_1、α-防御素和IL-17表达的临床研究[J].实用临床医药杂志,2015,19(7):47-49.
[2]王炳英.埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性消化性溃疡效果比较[J].山东医药,2015,55(38):77-78.
[3]黄盖,田邦妮,陈五一.雷贝拉唑与奥美拉唑三联七日用药方案治疗幽门螺杆菌相关性消化性溃疡的比较研究[J].现代中西医结合杂志,2015,24(5):495-497.
[4]杨忠兰,吴云峰,田茂超.雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌阳性消化性溃疡疗效及预后分析[J].中国现代医学杂志,2015,25(18):91-94.
[5]葛均波,徐永健.内科学(第8版)[M].北京:人民卫生出版社,2013:369.
[6]曹静,李长生.消化性溃疡行康复新液联合雷贝拉唑三联疗法的疗效及对炎性因子和血液流变学的影响[J].现代消化及介入诊疗,2016,21(2):217-219.
[7]许学新,朱晖,陆一峰,等.阿莫西林、雷贝拉唑联合克拉霉素治疗Hp相关消化性溃疡的疗效[J].现代生物医学进展,2015,15(34):6711-6713.
[8]朱延红,吴英杰,张春莉.雷贝拉唑与奥美拉唑四联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效比较[J].药物评价研究,2017,40(6):836-839.
[9]王晓霞.雷贝拉唑三联与奥美拉唑三联治疗消化性溃疡的比较[J].现代临床医学,2013,39(2):114-115.
[10]姜源,田莉,金成,等.雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效观察[J].现代消化及介入诊疗,2017,22(2):226-228.
[2]王炳英.埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性消化性溃疡效果比较[J].山东医药,2015,55(38):77-78.
[3]黄盖,田邦妮,陈五一.雷贝拉唑与奥美拉唑三联七日用药方案治疗幽门螺杆菌相关性消化性溃疡的比较研究[J].现代中西医结合杂志,2015,24(5):495-497.
[4]杨忠兰,吴云峰,田茂超.雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌阳性消化性溃疡疗效及预后分析[J].中国现代医学杂志,2015,25(18):91-94.
[5]葛均波,徐永健.内科学(第8版)[M].北京:人民卫生出版社,2013:369.
[6]曹静,李长生.消化性溃疡行康复新液联合雷贝拉唑三联疗法的疗效及对炎性因子和血液流变学的影响[J].现代消化及介入诊疗,2016,21(2):217-219.
[7]许学新,朱晖,陆一峰,等.阿莫西林、雷贝拉唑联合克拉霉素治疗Hp相关消化性溃疡的疗效[J].现代生物医学进展,2015,15(34):6711-6713.
[8]朱延红,吴英杰,张春莉.雷贝拉唑与奥美拉唑四联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效比较[J].药物评价研究,2017,40(6):836-839.
[9]王晓霞.雷贝拉唑三联与奥美拉唑三联治疗消化性溃疡的比较[J].现代临床医学,2013,39(2):114-115.
[10]姜源,田莉,金成,等.雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效观察[J].现代消化及介入诊疗,2017,22(2):226-228.